Drugs · Entity Annotation Prototype (beta)

11articles mentioning drugs

44drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: PBO ×

PBO

This drug is selected. Its supporting articles are shown below.

PBO11

Articles mentioning PBO

11 articles · page 1 of 1

PT4:01 Achievement of treat to target measures with upadacitinib in patients with systemic lupus erythematosus: phase 2 randomized SLEek clinical trial results

lupusscimed · abstract · 2026-03-01 · 8 matching annotations

91.7%

upadacitinib PBO UPA

…978520) was to evaluate the achievement of LLDAS and DORIS with upadacitinib (UPA) monotherapy (30 mg) vs placebo (PBO).Methods LLDAS and DO…

P.261 The efficacy and safety of divozilimab, anti-CD20 monoclonal antibody in patients with systemic sclerosis

jsrd · abstract · 2026-06-05 · 7 matching annotations

87.2%

Divozilimab DIV PBO mycophenolate mofetil MMF

…. There were no severe and serious ARs in DIV group.Conclusions Divozilimab treatment leads to significant decrease of skin fibrosis compar…

O61 Efficacy and safety of obefazimod in moderate-to-severe ulcerative colitis: 8-week phase 3 ABTECT induction trial results

gutjnl · abstract · 2026-06-23 · 6 matching annotations

87.6%

Obe-25 Obe-25-PBO Obe-50 Obefazimod Obe Obe-50-PBO

…rted at least one TEAE were 59.4%, 46.9%, and 53.2% for Obe-50, Obe-25, and PBO, respectively in ABTECT-1 and 61.0%, 50.9%, and 48.4% …

P171 Efficacy and safety of icotrokinra, a targeted oral peptide that blocks il-23 receptor activation, in ulcerative colitis: results from ANTHEM-UC

gutjnl · abstract · 2026-06-23 · 5 matching annotations

77.4%

vedolizumab ustekinumab ICO icotrokinra 6-MP AZA PBO ulcerative colitis

… ≥2, and inadequate response/intolerance (IR) to TNFa blockers, vedolizumab, ustekinumab, JAK inhibitors, or S1P receptor modulators (BIO/J…

O51 Long-term elafibranor in primary sclerosing cholangitis (PSC): interim safety and efficacy data from the ELMWOOD open-label extension (OLE) trial

gutjnl · abstract · 2026-06-23 · 4 matching annotations

83.1%

ELA elafibranor PBO

…pleted the DBP, 63 (98.4%) entered the OLE; 22 (100%) continued ELA 120mg treatment, and 20 (95.2%) and 21 (100%) crossed over from…

PT4:08 Impact of clinically important improvements in patient-reported outcomes on disease activity in patients with systemic lupus erythematosus treated with upadacitinib or placebo

lupusscimed · abstract · 2026-03-01 · 4 matching annotations

85.7%

upadacitinib PBO UPA SLE SLEek

…ion of patients achieving SRI-4, BICLA, or LLDAS responses with upadacitinib vs placebo based on changes in MCID for (A) FACIT-fatigue, (B) …

S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

lupusscimed · abstract · 2026-03-01 · 4 matching annotations

77.6%

dapirolizumab pegol DZP prednisone PBO BILAG-2004

…using data from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP, a novel CD40L inhibitor, consists of a polyethylene …

PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency trial

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

80.5%

obinutuzumab OBI PBO ST lupus nephritis NCT04221477

…es The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achie…

P176 Effects of subcutaneous guselkumab induction and maintenance on histologic outcomes in moderate-to-severe crohn’s disease in the phase 3 GRAVITI study

gutjnl · abstract · 2026-06-23 · 1 matching annotations

76.1%

GUS Guselkumab PBO Robarts Histopathology Index CD Crohn’s disease

…mg SC q4w maintenance vs PBO also achieved histologic response (GUS 100 mg SC q8w 49.5% and GUS 200 mg SC q4w 63.6% vs 10.6% PBO), …

P191 Intravenous and subcutaneous guselkumab induction are efficacious in crohn’s disease patients with high baseline disease severity: GALAXI and GRAVITI results

gutjnl · abstract · 2026-06-23 · 1 matching annotations

80.8%

GUS

… (≤12 [IV: GUS=43%, PBO=21%; SC: GUS=52%, PBO=24%] and >12 [IV: GUS=53% vs PBO=16%; SC: GUS=62% vs PBO=18%]), baseline CRP (≤3mg/L …

PT4:04 Achievement of low disease activity and remission in patients with SLE treated with dapirolizumab pegol: updated 48-week analyses from a phase 3 trial including lower glucocorticoid dose criteria

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

76.9%

dapirolizumab pegol DZP prednisone PBO SLE Lupus NCT04294667

… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…

Browse drugs

PBO

Articles mentioning PBO